Replies to post #23078 on Biotech Values

[poorgradstudent]

>But my enthusiasm with anormed's drug is it has also an ccr5 inhibitor.<

Really?

I assume that you've been following this class, and the fate of some of the candidates. What specifically is special about anormed's that you feel will allow it to secure a different fate?

[rfj1862]

AOM

>it has also an ccr5 inhibitor<

Twice the number of drugs = two or more times the risk for AEs, toxicities, and drug interactions.

If a company focusing on HIV comes up with a drug in any class that provides efficacy equivalent to currently available agents but with extremely good tolerability, I'd be encouraged to bite.

In my opinion, the real advances in HIV therapy no longer lie with developing novel classes. Instead, improving tolerability is the key.

HIV is a lifelong disease, the ability to live with it without suffering all the AEs associated with current agents would be an impressive advance. Still waiting....